Lakewood-Amedex reports promising AMR data for Nu-3 in iDFU

Lakewood-Amedex Biotherapeutics has announced promising data on AMR for its lead compound, Nu-3, which is being developed as a topical treatment for iDFU. Laboratory experiments exposed E. coli and MRSA to Nu-3 for 21 days. The minimum inhibitory concentration (MIC) changed in E. coli, while MRSA showed no change. Nu-3 maintained its original MIC when tested on bacteria that had developed resistance to ciprofloxacin, suggesting no cross-resistance. Credit: angellodeco/Shutterstock.com. Lakewood-Amedex Biotherapeutics has announced promising data on antimicrobial resistance (AMR) for its lead compound, Nu-3, which is being developed as a topical treatment for infected diabetic foot ulcers (iDFU). Nu-3 belongs…

Source: Clinical Trials Arena